These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21376479)

  • 1. Conference on abuse liability and appeal of tobacco products: conclusions and recommendations.
    Henningfield JE; Hatsukami DK; Zeller M; Peters E
    Drug Alcohol Depend; 2011 Jul; 116(1-3):1-7. PubMed ID: 21376479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Abuse Liability Assessment of Tobacco and Nicotine Products: Approaches for Meeting Current Regulatory Recommendations.
    Vansickel A; Baxter S; Sherwood N; Kong M; Campbell L
    Nicotine Tob Res; 2022 Feb; 24(3):295-305. PubMed ID: 34498698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of pyrazines in cigarettes and how additives might be used to enhance tobacco addiction.
    Alpert HR; Agaku IT; Connolly GN
    Tob Control; 2016 Jul; 25(4):444-50. PubMed ID: 26063608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consortium on Methods Evaluating Tobacco: Research Tools to Inform US Food and Drug Administration Regulation of Snus.
    Berman ML; Bickel WK; Harris AC; LeSage MG; O'Connor RJ; Stepanov I; Shields PG; Hatsukami DK
    Nicotine Tob Res; 2018 Sep; 20(11):1292-1300. PubMed ID: 29059363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotine reduction revisited: science and future directions.
    Hatsukami DK; Perkins KA; Lesage MG; Ashley DL; Henningfield JE; Benowitz NL; Backinger CL; Zeller M
    Tob Control; 2010 Oct; 19(5):e1-10. PubMed ID: 20876072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introductory notes on the tobacco problem.
    Slade J
    Nicotine Tob Res; 1999; 1 Suppl 2():S27-30. PubMed ID: 11768183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar precipitated withdrawal effects on intracranial self-stimulation during chronic infusion of an e-cigarette liquid or nicotine alone.
    Harris AC; Muelken P; Smethells JR; Krueger M; LeSage MG
    Pharmacol Biochem Behav; 2017 Oct; 161():1-5. PubMed ID: 28867606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Inventory of Methods for the Assessment of Additive Increased Addictiveness of Tobacco Products.
    van de Nobelen S; Kienhuis AS; Talhout R
    Nicotine Tob Res; 2016 Jul; 18(7):1546-55. PubMed ID: 26817491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes.
    Dunsby J; Bero L
    Tob Control; 2004 Dec; 13(4):362-9. PubMed ID: 15564619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No sisyphean task: how the FDA can regulate electronic cigarettes.
    Paradise J
    Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse liability assessment of tobacco products including potential reduced exposure products.
    Carter LP; Stitzer ML; Henningfield JE; O'Connor RJ; Cummings KM; Hatsukami DK
    Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3241-62. PubMed ID: 19959676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobacco and nicotine product testing.
    Hatsukami DK; Biener L; Leischow SJ; Zeller MR
    Nicotine Tob Res; 2012 Jan; 14(1):7-17. PubMed ID: 21460383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation.
    Harris AC; Tally L; Schmidt CE; Muelken P; Stepanov I; Saha S; Vogel RI; LeSage MG
    Drug Alcohol Depend; 2015 Feb; 147():60-7. PubMed ID: 25561387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could science-based regulation make tobacco products less addictive?
    Henningfield JE; Zeller M
    Yale J Health Policy Law Ethics; 2002; 3(1):127-38. PubMed ID: 12825431
    [No Abstract]   [Full Text] [Related]  

  • 15. Postmarketing surveillance for "modified-risk" tobacco products.
    O'Connor RJ
    Nicotine Tob Res; 2012 Jan; 14(1):29-42. PubMed ID: 21330282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy and health implications of using the U.S. Food and Drug Administration product design approach in reducing tobacco product risk.
    Givel M
    Curr Drug Abuse Rev; 2008 Jun; 1(2):135-41. PubMed ID: 19630712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's new plan to reduce the nicotine in cigarettes to sub-addictive levels could be a game-changer.
    Proctor RN
    Tob Control; 2016 Sep; 26(5):487-488. PubMed ID: 28831030
    [No Abstract]   [Full Text] [Related]  

  • 18. Tobacco use as drug addiction: the scientific foundation.
    Henningfield JE; Fant RV
    Nicotine Tob Res; 1999; 1 Suppl 2():S31-5. PubMed ID: 11768184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of multiple tobacco products in a national sample of persons enrolled in addiction treatment.
    Guydish J; Tajima B; Pramod S; Le T; Gubner NR; Campbell B; Roman P
    Drug Alcohol Depend; 2016 Sep; 166():93-9. PubMed ID: 27449271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The scientific basis of tobacco product regulation.
    WHO Study Group
    World Health Organ Tech Rep Ser; 2007; (945):1-112, back cover. PubMed ID: 17802809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.